Trial Profile
Phase 2 study of afatinib in advanced elderly NSCLC patients harboring sensitive EGFR mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2019
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 26 Sep 2018 Status changed from recruiting to completed, according to results presented at the 19th World Conference on Lung Cancer.
- 13 Aug 2014 New trial record